Leerink Partnrs Forecasts Increased Earnings for Immunocore

Immunocore Holdings plc (NASDAQ:IMCR) – Stock analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Immunocore in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.27) per share for the quarter, up from their previous estimate of ($0.39). The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($2.22) EPS.

A number of other equities analysts have also weighed in on IMCR. Oppenheimer upped their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Mizuho dropped their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $58.13.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $28.55 on Monday. The firm has a market cap of $1.43 billion, a PE ratio of -30.05 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a 1-year low of $23.15 and a 1-year high of $58.36. The company has a fifty day moving average price of $28.75 and a 200 day moving average price of $30.10.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. During the same quarter in the previous year, the business earned ($0.49) EPS. The firm’s revenue was up 33.6% on a year-over-year basis.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunocore

Several hedge funds and other institutional investors have recently bought and sold shares of IMCR. Principal Financial Group Inc. increased its stake in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after purchasing an additional 27,598 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in Immunocore by 36.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company’s stock valued at $1,121,000 after purchasing an additional 10,217 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after buying an additional 960 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock valued at $949,000 after buying an additional 1,616 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.